# Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

> **NCT06959082** · PHASE2 · RECRUITING · sponsor: **VSPharmTech Co.,Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Cancer Squamous Cell Carcinoma

## Interventions

- **DRUG:** VS-101
- **DRUG:** Cisplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT06959082
- **Lead sponsor:** VSPharmTech Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959082, "Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06959082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*